“Pharma is under a lot of government and public scrutiny. This industry also runs on meetings. You put those two facts together, and you can see that a meeting can expose pharma to significant risk of enforcement activity if not done correctly,”...
While talking with various CME industry stakeholders about peer review of CME content during the past months, I observed a lack of consistency in the definition of the term, employment of a process, and reasons for using or not using reviews...
When the Office of Inspector General issued its pharma marketing guidance in 2003, some experts predicted that drug companies would initially curtail their excesses, and after a while the feds would ease up and the pendulum would swing back to the...
When Susan Owens, manager, Travel and Meeting Services, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., sent her electronic request for proposal to the Sheraton New York Hotel and Towers recently, you can imagine a bit of confetti...